丽珠集团(000513.SZ)：公司2025年共有194个产品纳入国家医保目录

Core Viewpoint - The company, Lijun Group, announced that it has successfully included 194 products in the National Medical Insurance Directory for 2025, which includes 92 Class A and 102 Class B products [1] Group 1: Product Inclusion - The injectable Aripiprazole microspheres have been included in the National Medical Insurance Directory for the first time through negotiations [1] - The injectable Triptorelin acetate microspheres have a newly added indication [1] - The injectable Esomeprazole sodium has successfully renewed its contract [1]